

4 March 2021

*This press release is an English translation of the Swedish original. In the event of any discrepancies, the Swedish version shall prevail.*

## Last day of trading in BTA

**Stayble Therapeutics AB (“Stayble” or the “Company”) hereby announces that the last day of trading in Paid Subscription Shares (Sw. BTA) will be on 8 March 2021 and stop day will be on 10 March 2021.**

During February 2021, Stayble conducted a successful rights issue, which provided the Company approximately SEK 41.5 million before deduction of transaction related costs. The rights issue has now been registered with the Swedish Companies Registration Office (Sw. Bolagsverket) and the last day of trading in BTA will be on 8 March 2021 and stop day will be on 10 March 2021. The shares are estimated to be delivered on the shareholder’s account on 12 March 2021.

### Advisors

Sedermersa Fondkommission is the financial adviser, Markets & Corporate Law Nordic AB is the legal adviser and Nordic Issuing is acting as issuing agency in connection with the rights issue.

### For more information about the rights issue

Sedermersa Fondkommission

Phone: +46 40 615 14 10

E-mail: [info@sedermersa.se](mailto:info@sedermersa.se)

[www.sedermersa.se](http://www.sedermersa.se)

### For more information about Stayble

Andreas Gerward, CEO Stayble Therapeutics AB

E-mail: [andreas.gerward@stayble.se](mailto:andreas.gerward@stayble.se)

Phone: +46 730 808 397

### About Stayble Therapeutics AB

Stayble is a clinical stage pharmaceutical company developing the injection treatment STA363 for disc-related low back pain. The treatment is aimed at patients whose back pain persists after physiotherapy and painkillers. The injection is given once, and the effect is expected to remain throughout the entirety of the patient’s life and to require minimal rehabilitation. The Company is now focusing on the continued clinical development and is currently conducting a clinical phase 2b study. Stayble’s vision is to develop STA363 as a new standard treatment for patients suffering from chronic disc-related low back pain.

Mangold Fondkommission AB is the Company’s Certified Adviser and can be reached at +46 (0) 8 503 015 50 or e-mail [ca@mangold.se](mailto:ca@mangold.se)